Clinical implications of LDH isoenzymes in hemolysis and continuous-flow left ventricular assist device-induced thrombosis.
Jonathan S GordonChelsey T WoodJessica G Y LucRyan A WatsonElizabeth J MaynesJae Hwan ChoiRohinton J MorrisHoward Todd MasseyAmy L ThrockmortonVakhtang TchantchaleishviliPublished in: Artificial organs (2019)
Pump-induced thrombosis continues to be a major complication of continuous-flow left ventricular assist devices (CF-LVADs), which increases the risks of thromboembolic stroke, peripheral thromboembolism, reduced pump flow, pump failure, cardiogenic shock, and death. This is confounded by the fact that there is currently no direct measure for a proper diagnosis during pump support. Given the severity of this complication and its required treatment, the ability to accurately differentiate CF-LVAD pump thrombosis from other complications is vital. Hemolysis measured by elevated lactate dehydrogenase (LDH) enzyme levels, when there is clinical suspicion of pump-induced thrombosis, is currently accepted as an important metric used by clinicians for diagnosis; however, LDH is a relatively nonspecific finding. LDH exists as five isoenzymes in the body, each with a unique tissue distribution. CF-LVAD pump thrombosis has been associated with elevated serum LDH-1 and LDH-2, as well as decreased LDH-4 and LDH-5. Herein, we review the various isoenzymes of LDH and their utility in differentiating hemolysis seen in CF-LVAD pump thrombosis from other physiologic and pathologic conditions as reported in the literature.
Keyphrases
- pulmonary embolism
- left ventricular assist device
- cystic fibrosis
- high glucose
- left ventricular
- diabetic rats
- systematic review
- heart failure
- drug induced
- squamous cell carcinoma
- magnetic resonance
- acute myocardial infarction
- risk factors
- aortic valve
- transcatheter aortic valve replacement
- human health
- ejection fraction
- stress induced